tocilizumab pre-treatment reduced cytokine release syndrome in rrmm pts receiving cevostamab.
Published 1 year ago • 535 plays • Length 10:29Download video MP4
Download video MP3
Similar videos
-
4:30
majestec-1: longer follow-up teclistamab tocilizumab prophylaxis for crs in rr multiple myeloma
-
8:36
alnuctamab, a bcma x cd3 t-cell engager, in pts with relapsed/refractory multiple myeloma
-
9:57
teclistamab, a bcma × cd3 bispecific antibody, in pts with rrmm: updated phase 1 results
-
3:03:13
imf patient & family webinar - new frontiers in myeloma care
-
2:56:05
advances in myeloma treatments: what patients & caregivers need to know
-
4:16
tocilizumab in multiple myeloma patients
-
8:12
evaluating teclistamab in relapsed and/or refractory multiple myeloma
-
1:02
outcomes of patients with myeloma receiving fixed-duration cevostamab
-
2:08
longer-term follow-up of prophylactic tocilizumab for the reduction of crs in the majestec-1 trial
-
1:10
latest developments in the treatment of emd in myeloma
-
0:55
the management of cytokine release syndrome
-
1:39
the next five years of multiple myeloma treatment
-
2:30
a new era of treatment for multiple myeloma
-
1:25
how are cytogenetics used in myeloma care?
-
3:00
processes leading to the development of hyperdiploidy in multiple myeloma
-
1:47
insights into the efficacy of linvoseltamab in the treatment of r/r multiple myeloma
-
2:06:02
recent advances in the mechanism & treatment of immune thrmobocytopenia
-
1:22
long-term follow-up results of tourmaline-mm2: ird vs pbo-rd in multiple myeloma
-
1:23
evaluating the sensitivity of liquid biopsy in patients with extramedullary multiple myeloma